RxDoctor Payments Data

Laura Hubbard, MD

Family Medicine · Hays, NCNPI 1457450249

Payments from drug & device makers

$5,390in general payments, 2019–2025

Across 335 payments — averaging $16.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$758
  • Novo Nordisk$667
  • AstraZeneca$471
  • GSK$462
  • Lilly USA, LLC$358
  • Boehringer Ingelheim$326
  • plus $2K from 39 others

What the payments were for

  • Food & beverage$5,390100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$5,390 in reported general payments places this provider in the 90th percentile of 3,444 family medicine providers in North Carolina.

See all family medicine providers in North Carolina

Medicare billing

Part B allowed, 2024
$47,772
Medicare patients
112
Services billed
676

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban223$180,889
Trelegy ElliptaFluticasone/Umeclidin/Vilanter113$96,756
Tresiba Flextouch U-200Insulin Degludec61$94,376
HumiraAdalimumab11$88,637
FarxigaDapagliflozin Propanediol92$77,812
JardianceEmpagliflozin81$70,854
OzempicSemaglutide58$63,130
VascepaIcosapent Ethyl67$53,713
MyrbetriqMirabegron75$53,084
MounjaroTirzepatide40$50,937
XareltoRivaroxaban46$40,096
Tresiba Flextouch U-100Insulin Degludec50$33,498
JanuviaSitagliptin Phosphate33$31,289
AptiomEslicarbazepine Acetate13$30,945
VraylarCariprazine Hcl23$30,763

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$248$180,889223 claims
AbbVieHumira, Vraylar, Linzess$758$141,56967 claims
GSKTrelegy Ellipta, Breo Ellipta$462$115,104148 claims
Novo NordiskOzempic, Rybelsus$667$92,59081 claims
Boehringer IngelheimJardiance, Tradjenta$326$87,19198 claims
AstraZenecaFarxiga, Symbicort$471$85,314117 claims
Astellas Pharma US IncMyrbetriq$60$53,08475 claims
Lilly USA, LLCMounjaro$358$50,93740 claims
Johnson & JohnsonXarelto$138$40,09646 claims
MerckJanuvia$16$31,28933 claims
Sunovion Pharmaceuticals Inc.Aptiom$97$30,94513 claims
BayerKerendia$140$21,70420 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 3,444 family medicine providers in North Carolina.

Other family medicine in Hays

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →